Abstract
The prevalence of thyroid diseases including autoimmune hyperthyroidism (Graves’ disease), autoimmune thyroiditis, and different forms of thyroid cancer is increasing every year, while the effectiveness of their treatment remains low and is limited, mainly, to replacement therapy with thyroid hormones and surgical and radioisotope methods. This review presents the current state of the problem of pharmacological correction in thyroid diseases including new approaches to the regulation of the functional activity of the components of the thyroid hormone synthesis system in thyroid follicular cells, in particular, its initial, sensory component, the thyroid-stimulating hormone receptor. Among the drugs that are currently being developed, it is necessary to focus on allosteric regulators of the thyroid-stimulating hormone receptor, specific antibodies to it, as well as selective agonists of the β-isoform of thyroid hormone receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Siberian Journal of Clinical and Experimental Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
